Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK cells but also from CD16- CD56dim NK cells

Scandinavian Journal of Immunology

Volumn 65, Issue 2, 2007, Pages 126-138

  Takahashi, E ^a   Kuranaga, N ^a   Satoh, K ^a   Habu, Y ^a   Shinomiya, N ^a   Asano, T ^a   Seki, S ^a   Hayakawa, M ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; ANTINEOPLASTIC AGENT; CYTOKINE; FC RECEPTOR; FLUORESCEIN DERIVATIVE; HLA ANTIGEN CLASS 1; PICIBANIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CD16+ CD56 CELL; CELL CULTURE; CELL FUNCTION; CELL SELECTION; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE SUBPOPULATION; CHEMISTRY; DRUG EFFECT; IMMUNOLOGY; MONONUCLEAR CELL; NEOPLASM;

ANTIGENS, CD56; ANTINEOPLASTIC AGENTS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FLUORESCEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NEOPLASMS; PICIBANIL; RECEPTORS, IGG; STREPTOCOCCUS PYOGENES; T-LYMPHOCYTE SUBSETS;

EID: 33846619756     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01883.x     Document Type: Article

References (45)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376.
2. Bancroft GJ. The role of natural killer cells in innate resistance to infection. Curr Opin Immunol 1993;5:503-10.
3. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
4. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-6.
5. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-38.
6. Ellis TM, Fisher RI. Functional heterogeneity of Leu 19"bright" + and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol 1989;142:2949-54.
7. Carson WE, Fehniger TA, Caligiuri MA. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 1997;27:354-60.
8. Cooper MA, Fehniger TA, Turner SC et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-51.
9. Jacobs R, Hintzen G, Kemper A et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001;31:3121-7.
10. Moller MJ, Kammerer R, von Kleist S. A distinct distribution of natural killer cell subgroups in human tissues and blood. Int J Cancer 1998;78:533-8.
11. Drake PM, Gunn MD, Charo IF et al. Human placental cytotrophoblasts attract monocytes and CD56(bright) natural killer cells via the actions of monocyte inflammatory protein 1alpha. J Exp Med 2001;193:1199-212.
12. Fehniger TA, Cooper MA, Nuovo GJ et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003;101:3052-7.
13. Ohkawa T, Seki S, Dobashi H et al. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001;103:281-90.
14. Hashimoto W, Takeda K, Anzai R et al. Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 1995;154:4333-40.
15. Takeda K, Seki S, Ogasawara K et al. Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 1996;156:3366-73.
16. Cui J, Shin T, Kawano T et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-6.
17. Seki S, Habu Y, Kawamura T et al. The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev 2000;174:35-46.
18. Nakagawa R, Nagafune I, Tazunoki Y et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 2001; 166:6578-84.
19. Nakagawa R, Inui T, Nagafune I et al. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide. J Immunol 2004; 172:6550-7.
20. Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. Human NK-cell receptors. Immunol Today 2000;21:420-2.
21. Biassoni R, Cantoni C, Pende D et al. Human natural killer cell receptors and co-receptors. Immunol Rev 2001;181:203-14.
22. Katsuoka Y, Baba S, Hata M, Tazaki H. Transplantation of human renal cell carcinoma to the nude mice: as an intermediate of in vivo and in vitro studies. J Urol 1976;115:373-6.
23. Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 1990;50:5531-6.
24. Carson WE, Fehniger TA, Haldar S et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997;99:937-43.
25. Gumperz JE, Valiante NM, Parham P, Lanier LL, Tyan D. Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype. J Exp Med 1996;183:1817-27.
26. Abo T, Sugawara S, Seki S et al. Induction of human TCR gamma delta + and TCR gamma delta-CD2+CD3- double negative lymphocytes by bacterial stimulation. Int Immunol 1990;2:775-85.
27. Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 1992;79:3239-44.
28. Dilloo D, Laws HJ, Hanenberg H, Korholz D, Nurnberger W, Burdach SE. Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors. Exp Hematol 1994;22:1081-8.
29. Raspadori D, Lauria F, Ventura MA et al. Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas. Ann Hematol 1995;71:175-9.
30. Fehniger TA, Shah MH, Turner MJ et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999;162:4511-20.
31. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004;173:6418-26.
32. Vitale M, Della Chiesa M, Carlomagno S et al. The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 2004;34:1715-22.
33. Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol 1992;22:1-6.
34. Robertson MJ, Soiffer RJ, Wolf SF et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992;175:779-88.
35. Matos ME, Schnier GS, Beecher MS, Ashman LK, William DE, Caligiuri MA. Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 1993;178:1079-84.
36. Bluman EM, Schnier GS, Avalos BR et al. The c-kit ligand potentiates the allogeneic mixed lymphocyte reaction. Blood 1996;88:3887-93.
37. Loza MJ, Perussia B. The IL-12 signature: NK cell terminal CD56+ high stage and effector functions. J Immunol 2004;172:88-96.
38. Seki S, Abo T, Masuda T et al. Identification of activated T cell receptor gamma delta lymphocytes in the liver of tumor-bearing hosts. J Clin Invest 1990;86:409-15.
39. Perez-Villar JJ, Melero I, Navarro F et al. The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. J Immunol 1997;158:5736-43.
40. Pende D, Rivera P, Marcenaro S et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178-86.
41. Pende D, Parolini S, Pessino A et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-16.
42. Cantoni C, Bottino C, Vitale M et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999;189:787-96.
43. Sivori S, Pende D, Bottino C et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999;29:1656-66.
44. Yokoyama WM. Natural killer cell receptors. Curr Opin Immunol 1998;10:298-305.
45. Lanier LL. Face off - the interplay between activating and inhibitory immune receptors. Curr Opin Immunol 2001;13:326-31.